Newsroom

Novartis joins seven global companies to found the Value Balancing Alliance

For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.

Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.

Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.